Table 1 Frequency of APOE genotype by LIPGENE Dietary Fatty Acid Intervention Study center (n = 442).

From: APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome

 

All

Norway

Sweden

Ireland

Netherlands

UK

Poland

France

Spain

Genotype (n, %)

E2/E2

3 (0.7)

0 (0.0)

0 (0.0)

0 (0.0)

1 (2.2)

1 (1.7)

0 (0.0)

0 (0.0)

1 (1.4)

E2/E3

43 (9.7)

5 (8.7)

4 (8.3)

7 (12.0)

7 (15.9)

5 (8.6)

7 (10.3)

2 (5.1)

6 (8.5)

E2/E4

17 (3.8)

3 (5.2)

3 (6.2)

1 (1.7)

1 (2.2)

2 (3.4)

2 (2.9)

2 (5.1)

3 (4.2)

E3/E3

264 (59.7)

27 (47.3)

26 (54.1)

37 (63.8)

26 (59.0)

26 (44.8)

42 (61.8)

28 (71.8)

52 (74.2)

E3/E4

103 (23.3)

21 (36.8)

15 (31.2)

10 (17.2)

7 (15.9)

21 (36.2)

16 (23.5)

6 (15.3)

7 (10.0)

E4/E4

12 (2.7)

1 (1.7)

0 (0.0)

3 (5.1)

2 (4.5)

3 (5.1)

1 (1.4)

1 (2.5)

1 (1.4)

E2 carriersa

46 (10.4)

5 (8.7)

4 (8.3)

7 (12.0)

8 (18.1)

6 (10.3)

7 (10.2)

2 (5.1)

7 (10.0)

E4 carriersb

115 (26.0)

22 (38.6)

15 (31.2)

13 (22.4)

9 (20.4)

24 (41.3)

17 (24.9)

7 (17.9)

8 (11.4)

ALL

442

57

48

58

44

58

68

39

70

Allele frequency (%)

ε2

7.5

7.0

7.3

6.9

11.4

7.8

6.6

6.3

7.9

ε3

76.2

70.2

74.0

78.4

75.0

67.2

78.8

81.3

83.6

ε4

16.3

22.8

18.8

14.7

13.6

25.0

14.7

12.6

8.6

  1. Values are n (%). aGenotype groups combined; E2 carriers represent E2/E2 and E2/E3. bGenotype groups combined; E4 carriers represent E4/3 and E4/E4.